ClinicalTrials.gg
CompletedNCT07571824Updated Jul 1, 2026

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

A Phase 1 interventional study of Selegiline TDS 6 mg/24 hours and EMSAM® TDS 6 mg/24 hours in Healthy Adult Participants, sponsored by Corium Innovations, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Corium Innovations, Inc. (formerly part of Corium, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research study is to compare the bioavailability and adhesion of a generic Selegiline transdermal system (TDS) against the marketed comparator (EMSAM®) in healthy volunteers. Systemic and local safety and tolerability will be also observed and evaluated.

Read the detailed description

This is a single-dose, single-center, open-label, randomized crossover study (2 treatments, 2 periods and 4 sequences) of a generic test formulation of Selegiline TDS 6 mg/24 hours with the comparator EMSAM® TDS 6 mg/24 hours, with at least 56 days washout period, recruiting around 92 healthy male and female subjects.

For each study period, subjects will be admitted and confined in the clinical study site the night before the study day from at least 10 hours before dosing and they will be discharged once all PK, safety and tolerability are completed at 72 hours after dosing. Subjects will be required to return for subsequent PK, safety and tolerability at 84-hours post-dosing. The clinic will follow up by telephone 7 ± 3 days after subject completion of the study.

Trained study staff will also examine the patch application sites at scheduled time points and will score any skin reactions using standardized assessment scales. In addition, photographs of the patch application site will be taken to document adhesion status while the patch is being worn.

PK blood samples will be collected before dosing and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 27, 28, 32, 36, 40, 44, 48, 60, 72 and 84 hours after dosing.

Furthermore, the overall safety of the test product will be compared with that of the comparator product by monitoring and recording any adverse events, side effects, or discomfort experienced by subjects during the study.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

Corium Innovations, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

First submitted after Corium Innovations, Inc. left Corium, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female non-smoking subject.
  • A body weight ≤ 120 kg and a of 18.5-29.9 kg/m², inclusive.
  • Good health as determined by lack of abnormalities in the health assessments performed at screening, as deemed by the Investigator (or designee).
  • Able and willing to comply with protocol restrictions and required study procedures.

Exclusion criteria

Exclusion Criteria:

  • History of allergy, or idiosyncrasy to selegiline or other monoamine oxidase inhibitors (MAOIs), EMSAM® or any of its components, including glues/adhesives, or history of any drug hypersensitivity or intolerance that, in the opinion of the Investigator, would compromise the safety of the subject or integrity of the study.
  • Presence of any skin condition such as scratches, cuts, rash, scars, abrasions, excessive hair, tattoos or similar embodiments, moles, recently shaved skin, uneven skin texture, sunburned skin, or excessively oily skin at the application areas that, in the opinion of the Investigator, may affect the application or adhesion of the study patch or the systemic absorption of selegiline from the patch.
  • History or presence of any current dermatological condition such as atopy, psoriasis, eczema, chronic or atopic dermatitis, vitiligo, or urticaria which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of the study.
  • Personal (or immediate family history, as deemed relevant by the Investigator) of psychiatric disorders such as bipolar disorder, mania, hypomania, suicidal thoughts or behaviors occurring within 2 years before initial patch application that required the subject, or immediate family member (if applicable), to be hospitalized or undergo treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Selegiline Transdermal Delivery System on right arm

    Selegiline Transdermal Delivery System on right arm

    Drug: Selegiline TDS 6 mg/24 hours

  • Active comparator
    EMSAM® Transdermal Delivery System on left arm

    EMSAM® Transdermal Delivery System on left arm

    Drug: EMSAM® TDS 6 mg/24 hours

  • Active comparator
    EMSAM® Transdermal Delivery System on right arm

    EMSAM® Transdermal Delivery System on right arm

    Drug: EMSAM® TDS 6 mg/24 hours

  • Experimental
    Selegiline Transdermal Delivery System on left arm

    Selegiline Transdermal Delivery System on left arm

    Drug: Selegiline TDS 6 mg/24 hours

Interventions

  • DrugSelegiline TDS 6 mg/24 hours

    Selegiline TDS 6 mg/24 hours

  • DrugEMSAM® TDS 6 mg/24 hours

    EMSAM® TDS 6 mg/24 hours

06

What researchers measure

Primary outcomes

  1. Bioequivalence between test formulation of Selegiline TDS and EMSAM® TDS

    Bioequivalence between the test formulation of the Corium TDS, Selegiline Transdermal System, 6 mg/24 hours and the comparator, EMSAM®, 6 mg/24 hours will be assessed from pharmacokinetic sampling up to 84 hours following patch administration.

    Time frame: 84 hours following administration of Selegiline TDS and EMSAM® TDS

  2. Assessment of patch adhesion

    The primary endpoint of adhesion will be the Mean Adhesion Score (MAS) during the 24-hour application period. For the calculation of MAS, the highest adhesion score (representing the greatest degree of detachment) assessed at any time point will be used for subsequent time points until a higher score is assessed (Highest Observation Carried Forward \[HOCF\]). MAS for a specific subject and patch type will be derived from individual adhesion scores at each assessment time point averaged across all the equally spaced time points (except the baseline or time 0).

    Time frame: 24 hours following administration of Selegiline TDS and EMSAM® TDS

Secondary outcomes

  1. Safety and tolerability assessments

    Evaluation of safety and tolerability of the Selegiline TDS and EMSAM® TDS. Study staff will monitor adverse events and patch tolerability during this period.

    Time frame: From study enrollment through all study periods, up to 67 days.

07

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Las Vegas, Nevada 89121, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Jun 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
May 6, 2026
StartActual
Mar 23, 2026
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07571824
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Mar 23, 2026
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Jul 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion